20-valent pneumococcal conjugate vaccine
20-valent pneumococcal conjugate vaccine is a biological therapy with 10 clinical trials. Currently 3 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 7 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
0
Mid Stage
8
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
100.0%
7 of 7 finished
0.0%
0 ended early
3
trials recruiting
10
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study to Learn About How a New Pneumococcal Vaccine Works in Adults
A Study to Learn About the Safety of PREVENAR 20 Vaccine in Infants Aged Between Two to Six Months
A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and Taiwan
Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency
A Study to Learn About the Safety and Immune Response of 20vPnC in Adults in India.
Clinical Trials (10)
A Study to Learn About How a New Pneumococcal Vaccine Works in Adults
A Study to Learn About the Safety of PREVENAR 20 Vaccine in Infants Aged Between Two to Six Months
A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and Taiwan
Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency
A Study to Learn About the Safety and Immune Response of 20vPnC in Adults in India.
Safety and Immunogenicity of 20vPnC in Toddlers With 2 Prior Doses of Prevenar 13
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants
20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants
All 10 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 10